Stockscreener 앱 받기
1.1895
1.67%
0.0195
전일 마감가:
$1.17
열려 있는:
$1.18
하루 거래량:
71,681
Relative Volume:
0.02
시가총액:
$6.20M
수익:
$852.30K
순이익/손실:
$-21.37M
주가수익비율:
-0.0548
EPS:
-21.6981
순현금흐름:
$-19.06M
1주 성능:
-0.87%
1개월 성능:
-3.29%
6개월 성능:
-80.97%
1년 성능:
-94.71%
1일 변동 폭
$1.165
$1.20
1주일 범위
$1.12
$1.47
52주 변동 폭
$0.9631
$30.75
Geovax Labs Inc Stock (GOVX) Company Profile
명칭
Geovax Labs Inc
전화
678-384-7220
주소
1955 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.1898 | 6.15M | 852.30K | -21.37M | -19.06M | -21.70 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
615.95 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
899.37 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.10 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.36 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-04-15 | 재확인 | Alliance Global Partners | Buy |
| 2025-04-15 | 재확인 | D. Boral Capital | Buy |
| 2024-11-11 | 개시 | Alliance Global Partners | Buy |
| 2024-07-16 | 개시 | ROTH MKM | Buy |
| 2020-11-19 | 개시 | Maxim Group | Buy |
모두보기
Geovax Labs Inc 주식(GOVX)의 최신 뉴스
GOVX Q1 2026 Earnings: EPS Surprise of 41.89% as Loss Narrows from EstimatesConsensus Forecast Report - newsline.com
GeoVax Labs (GOVX) could find a support soon, here's why you should buy the stock now - MSN
GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
GeoVax Labs Company Profile & Introduction - Moomoo
[SCHEDULE 13G] GeoVax Labs, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Why Is GOVX Stock Falling Today? - Stocktwits
Q3 2025 GeoVax Labs Inc Earnings Call Transcript - GuruFocus
GeoVax Highlights Research Showing Gedeptin Could Enhance Checkpoint Inhibitor Responses in Resistant Tumors - MEXC
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses - Yahoo Finance
GOVX Q1 2026 Earnings: EPS Surprises to the Upside, Yet Stock Retreats 11.8%EPS Surprise History - newsline.com
GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
[EFFECT] GeoVax Labs, Inc. SEC Filing - Stock Titan
GeoVax Labs | EFFECT: Others - Moomoo
GOVX Technical Analysis | Trend, Signals & Chart Patterns | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill
GeoVax CEO Sees Renewed Strategic Focus on Vaccine Platforms Amid Industry Acquisitions - citybuzz -
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation - Yahoo Finance
GeoVax CEO Highlights Biothreat Readiness as FIFA World Cup 2026 Approaches - MEXC
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness - Yahoo Finance
Why is GeoVax Labs stock falling Tuesday? - MSN
GOVX Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances DevelopmentEarnings Growth Forecast - newsline.com
GOVX: GEO-MVA advances to phase III with expedited EMA review, targeting unmet global vaccine demand - TradingView
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - Investing.com
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
GeoVax CEO to Discuss Platform-Based Vaccine Technologies in Tribe Public Webinar - citybuzz -
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event - NewMediaWire
GeoVax Labs Inc. (GOVX) Q1 2026 Earnings: Narrower-Than-Expected Loss, No Revenue; Shares SlidePre-Announcement Alert - newsline.com
GOVX Q1 2026 Earnings: Narrower-than-Expected Loss Surprises MarketTech Earnings Analysis - The Legal Advocate
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW! - FinancialContent
GeoVax Labs (GOVX) Narrows Focus on Key Development Programs - GuruFocus
GOVX Faces 11% Decline Following Suspension of COVID Vaccine Ini - GuruFocus
GeoVax Labs (GOVX) Shifts Focus from COVID Vaccine to Smallpox P - GuruFocus
GeoVax Prioritizes GEO-MVA and Gedeptin, Discontinues COVID-19 Vaccine Development - citybuzz -
GeoVax (GOVX) resale S-1 shows 7.6M warrant shares and tight cash runway - Stock Titan
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R) - Yahoo Finance
How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks - Yahoo Finance
Roth MKM Maintains GeoVax Labs(GOVX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
GOVX Q1 2026 Earnings: Narrower Loss Surprises, Shares Surge Over 32%Earnings Call Q&A - The Legal Advocate
GOVX Jumps As GeoVax Wins Bullish Ebola Vaccine Call - timothysykes.com
Geovax Labs Analyst Ratings and Price Targets | NASDAQ:GOVX - Benzinga
Geovax Labs Inc (GOVX) Stock Price, Quote, News & History - Benzinga
GOVX Stock Jumps As Noble Capital Targets $10 On Ebola Vaccine Hopes - StocksToTrade
GOVX Stock Jumps As Noble Capital Reaffirms $10 Target - timothysykes.com
GeoVax Labs Q1 2026 Earnings: Significant EPS Beat Drives Stock SurgeRevenue Surprise History - Newser
Q1 2025 GeoVax Labs Inc Earnings Call Transcript - GuruFocus
Is GeoVax Labs (GOVX) Still a Buy After +15.92% Rally? 2026-05-20Trading Community - Newser
GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats - Benzinga
GeoVax Highlights Need for Flexible Vaccine Platforms Amid Bundibugyo Ebola Outbreak - MEXC
GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus Concerns - Stocktwits
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms - Yahoo Finance
GeoVax Labs Announces Private Placement Offering with Pre-Funded and Common Stock Purchase Warrants – Details and Agreements Included - Minichart
GeoVax Raises $3 Million via Private Placement Financing - TipRanks
Geovax Labs Inc (GOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.79%
0.89%
자본화:
|
볼륨(24시간):